{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T21:16:09Z","timestamp":1720559769643},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ctrv.2016.03.013","type":"journal-article","created":{"date-parts":[[2016,4,3]],"date-time":"2016-04-03T00:56:13Z","timestamp":1459644973000},"page":"27-34","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Thymic malignancies: Moving forward with new systemic treatments"],"prefix":"10.1016","volume":"46","author":[{"given":"J.","family":"Remon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.R.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.V.","family":"Bluthgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2016.03.013_b0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ejca.2012.02.047","article-title":"Rare thoracic cancers, including peritoneum mesothelioma","volume":"48","author":"Siesling","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0010","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0015","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1200\/JCO.2011.36.0487","article-title":"Thymic malignancies: from clinical management to targeted therapies","volume":"29","author":"Kelly","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JTO.0b013e318276241c","article-title":"Thymoma: a population-based study of the management and outcomes for the province of British Columbia","volume":"8","author":"Mariano","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2007.11.004","article-title":"Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy","volume":"44","author":"de Jong","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0030","doi-asserted-by":"crossref","first-page":"S1698","DOI":"10.1097\/JTO.0b013e31821e7b12","article-title":"A review of prognostic factors in thymic malignancies","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0035","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/era.12.29","article-title":"Chemotherapy and targeted agents for thymic malignancies","volume":"12","author":"Girard","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2016.03.013_b0040","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00432-014-1800-6","article-title":"Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy","volume":"141","author":"Okuma","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0045","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern cooperative oncology group, Southwest oncology group, and Southeastern cancer study group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"issue":"9, Suppl. 2","key":"10.1016\/j.ctrv.2016.03.013_b0050","first-page":"449","article-title":"Pan-European survey on thymic malignancies: a collaboration of the EORTC lung cancer group (LCG) with the RYTHMIC network","volume":"10","author":"Menis","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.ctrv.2016.03.013_b0055","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"ESMO guidelines committee. Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0060","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2014.11.006","article-title":"Pemetrexed in patients with thymic malignancies previously treated with chemotherapy","volume":"87","author":"Liang","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0065","first-page":"7079","article-title":"A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma","volume":"24","author":"Loehrer","year":"2006","journal-title":"ASCO Meeting Abstr"},{"key":"10.1016\/j.ctrv.2016.03.013_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-5002(13)70334-9","article-title":"Oral etoposide in pretreated advanced thymoma and thymic carcinoma. A French experience","volume":"80","author":"Boutros","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0075","first-page":"7580","article-title":"Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM)","volume":"33","author":"Wakelee","year":"2015","journal-title":"ASCO Meeting Abstr"},{"key":"10.1016\/j.ctrv.2016.03.013_b0080","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/JTO.0000000000000362","article-title":"Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan lung cancer group study 0803","volume":"9","author":"Inoue","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0085","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2217\/fon.14.144","article-title":"Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a phase II trial","volume":"10","author":"Palmieri","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0090","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.03.013_b0095","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/JTO.0000000000000298","article-title":"State of the art of genetic alterations in thymic epithelial tumors","volume":"9","author":"Rajan","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0100","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.3016","article-title":"A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors","volume":"46","author":"Petrini","year":"2014","journal-title":"Nat Genet"},{"issue":"9, Suppl. 2","key":"10.1016\/j.ctrv.2016.03.013_b0105","article-title":"Validation of a specific missense GT2FI mutation in more indolent thymic epithelial tumours","volume":"10","author":"Gennatas","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0110","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1038\/srep07336","article-title":"Mutations of epigenetic regulatory genes are common in thymic carcinomas","volume":"4","author":"Wang","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2016.03.013_b0115","doi-asserted-by":"crossref","first-page":"e66047","DOI":"10.1371\/journal.pone.0066047","article-title":"A gene signature to determine metastatic behavior in thymomas","volume":"8","author":"G\u00f6kmen-Polar","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2016.03.013_b0120","doi-asserted-by":"crossref","first-page":"890","DOI":"10.18632\/oncotarget.1015","article-title":"Thymoma patients treated in a phase I clinic at MD Anderson cancer center: responses to mTOR inhibitors and molecular analyses","volume":"4","author":"Wheler","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2016.03.013_b0125","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.lungcan.2015.06.014","article-title":"Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (phase I trials) at Gustave Roussy","volume":"89","author":"Kossai","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0130","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2014.58.2007","article-title":"Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial","volume":"33","author":"Lopez-Chavez","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0145","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/annonc\/mdr626","article-title":"Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors","volume":"23","author":"Schirosi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-011-1690-0","article-title":"Imatinib mesylate in thymic epithelial malignancies","volume":"69","author":"Palmieri","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0155","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0160","first-page":"8116","article-title":"Imatinib for the treatment of thymic carcinoma","volume":"26","author":"Salter","year":"2008","journal-title":"ASCO Meeting Abstr"},{"key":"10.1016\/j.ctrv.2016.03.013_b0165","first-page":"5105","article-title":"Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations","volume":"34","author":"Pagano","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2016.03.013_b0170","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/OTT.S58902","article-title":"Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E","volume":"7","author":"Catania","year":"2014","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ctrv.2016.03.013_b0175","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11523-012-0235-8","article-title":"Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma","volume":"7","author":"Neuhaus","year":"2012","journal-title":"Target Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2010.09.011","article-title":"Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation","volume":"71","author":"Di\u015fel","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0185","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1097\/JTO.0b013e3181f209b9","article-title":"Thymic tumors: relevant molecular data in the clinic","volume":"5","author":"Girard","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0190","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1093\/annonc\/mds147","article-title":"Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas","volume":"23","author":"Mimae","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0195","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jjco\/hyl028","article-title":"Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors","volume":"36","author":"Suzuki","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0200","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/cncr.20811","article-title":"Protein expression and gene amplification of epidermal growth factor receptor in thymomas","volume":"103","author":"Ionescu","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0205","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma","volume":"12","author":"Palmieri","year":"2007","journal-title":"Front Biosci"},{"key":"10.1016\/j.ctrv.2016.03.013_b0210","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0215","first-page":"19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"ASCO Meeting Abstr"},{"key":"10.1016\/j.ctrv.2016.03.013_b0220","first-page":"7068","article-title":"Phase II study of gefitinib treatment in advanced thymic malignancies","volume":"23","author":"Kurup","year":"2005","journal-title":"ASCO Meeting Abstr"},{"key":"10.1016\/j.ctrv.2016.03.013_b0225","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.lungcan.2012.05.108","article-title":"HER family receptor and ligand status in thymic carcinoma","volume":"77","author":"Weissferdt","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0230","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2559.2003.01663.x","article-title":"Expression of apoptosis-related markers and HER-2\/neu in thymic epithelial tumours","volume":"43","author":"Pan","year":"2003","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2016.03.013_b0235","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00280-013-2297-4","article-title":"Phase I study evaluating the combination of lapatinib (a Her2\/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West oncology group (SWOG) study S0528","volume":"72","author":"Gadgeel","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0240","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1158\/1078-0432.CCR-12-1158","article-title":"Phase I study of the antiangiogenic antibody bevacizumab and the mTOR\/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity","volume":"18","author":"Moroney","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.03.013_b0245","first-page":"7527","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"32","author":"Zucali","year":"2014","journal-title":"ASCO Meeting Abstr"},{"key":"10.1016\/j.ctrv.2016.03.013_b0250","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e3181e392a8","article-title":"Insulin-like growth factor-1 receptor expression in thymic malignancies","volume":"5","author":"Girard","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0255","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1002\/cncr.25367","article-title":"Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas","volume":"116","author":"Zucali","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0260","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0265","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.03.013_b0270","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0275","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","article-title":"A phase I\/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study","volume":"20","author":"Thomas","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.03.013_b0280","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lungcan.2014.05.010","article-title":"Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study","volume":"85","author":"Lattanzio","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0285","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","article-title":"Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus","volume":"190","author":"Cimpean","year":"2008","journal-title":"Ann Anat"},{"key":"10.1016\/j.ctrv.2016.03.013_b0290","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s005950170021","article-title":"Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms","volume":"31","author":"Sasaki","year":"2001","journal-title":"Surg Today"},{"key":"10.1016\/j.ctrv.2016.03.013_b0295","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ctrv.2016.03.013_b0300","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9, Suppl. 2","key":"10.1016\/j.ctrv.2016.03.013_b0305","article-title":"Sunitinib in patients with advanced thymoma and thymic carcinoma. Retrospective analysis from RYTHMIC database","volume":"10","author":"Remon","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0310","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.clgc.2014.11.004","article-title":"Efficacy and safety of an attenuated-dose sunitinib regimen in metastatic renal cell carcinoma: results from a prospective registry in Singapore","volume":"13","author":"Tan","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"268","key":"10.1016\/j.ctrv.2016.03.013_b0315","first-page":"e9","article-title":"Sunitinib dosing schedule 2\/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma","volume":"33","author":"Pan","year":"2015","journal-title":"Urol Oncol"},{"issue":"9, Suppl. 2","key":"10.1016\/j.ctrv.2016.03.013_b0320","article-title":"Clinical activity of lucitanib in advanced thymic epithelial tumors","volume":"10","author":"Besse","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0325","article-title":"Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma","author":"Rautiola","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2016.03.013_b0330","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2015.04.008","article-title":"A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies","volume":"89","author":"Gubens","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0335","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s10637-012-9898-3","article-title":"A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors","volume":"31","author":"Hong","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2016.03.013_b0340","first-page":"7526","article-title":"A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC)","volume":"32","author":"Besse","year":"2014","journal-title":"ASCO Meeting Abstr"},{"key":"10.1016\/j.ctrv.2016.03.013_b0345","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/030089161109700210","article-title":"Current role of 111In-DTPA-octreotide scintigraphy in diagnosis of thymic masses","volume":"97","author":"Guidoccio","year":"2011","journal-title":"Tumori"},{"key":"10.1016\/j.ctrv.2016.03.013_b0350","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1210\/endo.140.1.6398","article-title":"In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells","volume":"140","author":"Ferone","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2016.03.013_b0355","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/cncr.10374","article-title":"Somatostatin analogs and prednisone in advanced refractory thymic tumors","volume":"94","author":"Palmieri","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0360","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Eastern cooperative oncology group phase II trial. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern cooperative oncology group phase II trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0365","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer","volume":"31","author":"Paz-Ares","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0370","first-page":"7581","article-title":"Somatostatin analogs as maintenance therapy in heavily pretreated thymic epithelial tumors","volume":"33","author":"Palmieri","year":"2015","journal-title":"ASCO Meeting Abstr"},{"key":"10.1016\/j.ctrv.2016.03.013_b0375","first-page":"7582","article-title":"Effectiveness of somatostatin analogs plus prednisone in aggressive histotype and advanced stage of thymic epithelial tumors","volume":"33","author":"Ottaviano","year":"2015","journal-title":"ASCO Meeting Abstr"},{"key":"10.1016\/j.ctrv.2016.03.013_b0380","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2016.03.013_b0385","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.03.013_b0390","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.03.013_b0395","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.03.013_b0400","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2016.03.013_b0405","first-page":"7516","article-title":"Defining the immunologic phenotype of thymic epithelial tumors","volume":"33","author":"Naidoo","year":"2015","journal-title":"ASCO Meeting Abstr"},{"key":"10.1016\/j.ctrv.2016.03.013_b0410","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2016.03.013_b0415","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J Immunol"},{"issue":"9 Suppl.","key":"10.1016\/j.ctrv.2016.03.013_b0420","article-title":"Programmed cell death 1 ligand (PD-L1) expression in thymoma","volume":"10","author":"Yokoyama","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"9, Suppl. 2","key":"10.1016\/j.ctrv.2016.03.013_b0425","article-title":"The clinicopathological significance of PD-L1 expression in thymoma","volume":"10","author":"Takumi","year":"2015","journal-title":"J Thorac Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T02:14:49Z","timestamp":1567736089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216300020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":85,"alternative-id":["S0305737216300020"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.013","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thymic malignancies: Moving forward with new systemic treatments","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}